<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03710577</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0980</org_study_id>
    <nct_id>NCT03710577</nct_id>
  </id_info>
  <brief_title>Endocannabinoid and Psychological Responses to Yoga in Healthy Adults</brief_title>
  <official_title>Endocannabinoid and Psychological Responses to Yoga in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the acute effect of yoga on plasma levels of endocannabinoids and mood
      (i.e., mood disturbance, anxiety, pain) compared to one session of quiet rest. Participants
      completed one session of yoga and one session of quiet rest on two separate days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2017</start_date>
  <completion_date type="Actual">May 16, 2018</completion_date>
  <primary_completion_date type="Actual">May 16, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The proposed study is an acute, single group, crossover pilot study where participants will complete control and experimental conditions.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of N-arachidonoylethanolamine</measure>
    <time_frame>This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)</time_frame>
    <description>Plasma concentration of anandamide, one effector of the endocannabinoid system</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of 2-Arachidonoylglycerol (2-AG)</measure>
    <time_frame>This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)</time_frame>
    <description>Plasma concentration of 2-AG, one effector of the endocannabinoid system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Mood Disturbance (Profile of Mood States)</measure>
    <time_frame>This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)</time_frame>
    <description>65-item self-reported mood questionnaire that measures mood &quot;right now.&quot; Scores range from 0-200 with higher scores indicating higher mood disturbance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State Anxiety (State-Trait Anxiety Inventory)</measure>
    <time_frame>This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)</time_frame>
    <description>20-item self-reported anxiety questionnaire that measures anxiety &quot;right now.&quot; Scores range from 20-80 with higher scores indicating higher anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Pain (Short-form McGill Pain Questionnaire)</measure>
    <time_frame>This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)</time_frame>
    <description>15-item self-reported pain questionnaire that measures pain &quot;right now.&quot; Scores range from 0-45 with higher scores indicating higher pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Yoga</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 minutes of Vinyasa yoga</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quiet Rest</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>40 minutes of quiet rest</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Yoga</intervention_name>
    <description>1 session</description>
    <arm_group_label>Yoga</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Quiet Rest</intervention_name>
    <description>1 session</description>
    <arm_group_label>Quiet Rest</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  greater than or equal to 18 years old and &lt; 45 years old and

          -  report being healthy.

        Exclusion Criteria:

          -  Being pregnant or planning to become pregnant,

          -  currently smoking,

          -  having a history of light headedness or fainting during blood draws or physical
             activity,

          -  having a history of chest pain during physical activity,

          -  having a bone, joint, cardiac, or other medical condition that a doctor has said may
             be worsened by physical activity,

          -  taking medications for any chronic diseases such as high blood pressure or diabetes,

          -  responding 'Yes' to any of the seven questions on the Par-Q.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelli Koltyn, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin-Madison Natatorium</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>June 21, 2018</study_first_submitted>
  <study_first_submitted_qc>October 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2018</study_first_posted>
  <last_update_submitted>October 15, 2018</last_update_submitted>
  <last_update_submitted_qc>October 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT03710577/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

